X4 Pharmaceuticals (XFOR) Research & Development (2017 - 2025)

X4 Pharmaceuticals' Research & Development history runs 9 years deep, the most recent figure standing at $18.5 million for Q4 2025.

• Quarterly Research & Development fell 14.66% year-over-year to $18.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $72.7 million (down 10.93% YoY) and the FY2025 annual result came in at $72.7 million, down 10.93% from the prior year.
• Research & Development was $18.5 million for Q4 2025 at X4 Pharmaceuticals, up from $17.3 million in the prior quarter.
• Across five years, Research & Development topped out at $22.1 million in Q1 2023 and bottomed at $12.1 million in Q1 2021.
• A 5-year average of $16.9 million and a median of $17.8 million in 2025 frame the typical range for Research & Development.
• Annual changes were most pronounced in 2022 — Research & Development soared 56.34% — and 2023, when it decreased 19.68%.
• X4 Pharmaceuticals' Research & Development stood at $12.2 million in 2021, then jumped by 56.34% to $19.0 million in 2022, then dropped by 19.68% to $15.3 million in 2023, then soared by 42.1% to $21.7 million in 2024, then decreased by 14.66% to $18.5 million in 2025.
• Business Quant data shows XFOR's Research & Development at $18.5 million in Q4 2025, $17.3 million in Q3 2025, and $18.4 million in Q2 2025.